GlassScriptPhysician profile
Khaleel Sayeed
NPI 1942529623
$40,221.77
in general payments reported to CMS, 2019-2025
16 companies · $565 in 2025
The $565 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.36 · 2020: $18.31 · 2021: $229 · 2022: $27K · 2023: $7,226 · 2024: $4,691 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $2,009 · Travel and Lodging: $206 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,250.00 |
| Food and Beverage | $2,009.23 |
| Travel and Lodging | $205.92 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $38,134.00 | 2021-2024 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $510.12 | 2021-2025 | Farxiga |
| Travere Therapeutics, INC. | $481.43 | 2023-2025 | |
| Fresenius USA Marketing, INC. | $259.97 | 2022-2025 | Velphoro, Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.99 | 2023-2025 | Jardiance |
| Amgen INC. | $140.37 | 2019-2023 | Tavneos |
| Novartis Pharmaceuticals Corporation | $108.50 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.85 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $77.92 | 2024-2025 | Tarpeyo |
| Merck Sharp & Dohme LLC | $61.36 | 2025 | Prevymis |
| Mallinckrodt Enterprises LLC | $55.98 | 2019 | |
| Ardelyx, INC. | $45.23 | 2024 | Ibsrela |
| Nxstage Medical, INC. | $21.90 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $14.38 | 2019 | |
| Glaxosmithkline, LLC. | $11.77 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaleel Sayeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.